Group 1 - The company, Guohao Group, reported that its subsidiary, Guohao Real Estate, achieved revenue of 1.916 billion Singapore dollars for the fiscal year ending June 30, 2025, representing a year-on-year increase of 5.31% [1] - The company's shareholders' profit attributable to them was 107 million Singapore dollars, which reflects a year-on-year decrease of 16.71% [1] - The board of Guohao Real Estate proposed to declare an interim and final dividend of 7 cents per ordinary share [1]

格隆汇8月29日丨国浩集团(00053.HK)发布公告，截至2025年6月30日止六个月，国浩房地产实现收益 19.16亿新加坡元，同比增加5.3%；毛利为3.66亿新加坡元，同比减少7.2%；公司拥有人应占溢利为1.07 亿新加坡元，同比减少16.7%。 ...

國浩房地產有限公司 國浩房地產集團截至二零二五年六月三十日止 年度之財務業績摘要 (附註：「本公司」及「仙」分別指「國浩房地產」及「新加坡仙」。) | | 截至 2025 年 | 截至 2024 年 | | --- | --- | --- | | | 6 月 30 日止年度 | 6 月 30 日止年度 | | | | (重列)* | | | 千新加坡元 | 千新加坡元 | | 收益 | 1,916,402 | 1,819,751 | | 銷售成本 | (1,550,563) | (1,425,464) | | 毛利 | 365,839 | 394,287 | | 除稅前溢利 | 172,560 | 171,842 | | 稅項開支 | (33,747) | (75,804) | | 年內溢利 | 138,813 | 96,038 | | 應佔溢利： | | | | 本公司股東 | 107,050 | 128,531 | | 非控制權益 | 31,763 | (32,493) | | 年內溢利 | 138,813 | 96,038 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 ...

Group 1: Yunnan Baiyao Acquisition - Yunnan Baiyao announced a cash acquisition of 100% equity in An Guo Shi Ju Yao Tang for 660 million yuan [1] - Yunnan Baiyao is a leading company in the traditional Chinese medicine industry, with projected revenue exceeding 40 billion yuan and net profit reaching 4.749 billion yuan in 2024 [1] - An Guo Shi Ju Yao Tang specializes in the production and sales of traditional Chinese medicine pieces and has a strong profitability record, with a production capacity of 25,000 tons for traditional Chinese medicine pieces and 1,500 tons for formula granules [1] Group 2: Brain-Computer Interface (BCI) Sector - The BCI sector has seen significant stock performance, with an average increase of 48.67% in 2023, and several stocks, including Innovation Medical, have doubled in value [4][10] - Innovation Medical's stock reached a new high, with a year-to-date increase of 235.05%, despite the company reporting continuous net losses over the past six years [3][4] - The BCI technology is recognized as a key area for development in China's 14th Five-Year Plan, with a projected market size in the medical field reaching between 40 billion to 145 billion USD by 2030-2040 [8] Group 3: Research and Development in BCI - A significant breakthrough in BCI research was achieved by scientists who decoded "inner speech" with a 74% accuracy rate, which could aid patients with severe speech impairments [7] - The research involved implanting microelectrodes in the brain's motor cortex of participants with severe paralysis, demonstrating the potential for advanced human-computer interaction [7] - The BCI market in China is expected to grow from 3.2 billion yuan in 2024 to over 5.5 billion yuan by 2027, indicating a robust growth trajectory [8] Group 4: Company Participation in BCI - Various companies are engaging in the BCI industry through technology development, equipment provision, and strategic partnerships, with Innovation Medical investing in BCI-related firms [10] - Notable companies in the BCI space include Qiangnao Technology and Sanbo Brain Science, which are developing non-invasive BCI technologies [9][10] - A total of 27 BCI-related stocks have attracted institutional attention this year, with North Land Pharmaceutical receiving the most inquiries [11]

Group 1 - The Rank Group PLC, a subsidiary of Guohao Group (00053), reported revenue of £795 million for the fiscal year ending June 30, 2025, representing an 8.26% year-on-year increase [1] - The net profit for The Rank Group PLC reached £44.6 million, showing a significant year-on-year growth of 265.57% [1]

Core Viewpoint - The Rank Group PLC, a subsidiary of Guohao Group, reported a revenue of £795 million for the fiscal year ending June 30, 2025, reflecting an 8.26% year-on-year increase, and a net profit of £44.6 million, which represents a significant year-on-year growth of 265.57% [1] Financial Performance - Revenue reached £795 million, marking an 8.26% increase compared to the previous year [1] - Net profit amounted to £44.6 million, showing a substantial growth of 265.57% year-on-year [1]

附屬公司 THE RANK GROUP PLC 截至二零二五年六月三十日止年度之 業績公告 此公告乃國浩集團有限公司（「國浩」）根據《證券及期貨條例》第XIVA部及香港聯合交易所有限公司證 券上市規則第13.09(2)(a)條之規定而刊發，向國浩之股東提供其一間上市附屬公司THE RANK GROUP PLC 之財務資料。該上市附屬公司於二零二五年八月十四日公佈其截至二零二五年六月三十日止年度之初步業績 公告。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 股息 Rank的董事會將於其即將召開之股東週年大會上建議宣派截至二零二五年六月三十日止年度之末期股息每股1.95便 士（二零二四年：每股0.85便士）。 備註： Rank 集團截至二零 二 五 年 六 月三十日 止 年 度 之 初 步 業 績 公 告 詳情可於倫敦交易所網站 (http://www.londonstockexchange.com) 查閱，並登載於香港聯合交易所有限公司網站 (htt ...

Group 1: Financial Sector Performance - The financial sector experienced a collective surge, with banks, multi-financial services, insurance, and brokerage indices showing significant upward movement [4][6] - Agricultural Bank of China has seen a remarkable performance, achieving 10 out of 11 trading days of increases, with six consecutive days reaching historical highs [4] - The rise in financial stocks is likely linked to the peak reporting season for semi-annual results, with most listed banks reporting positive net profit growth [4][5] Group 2: Medical Device Market Growth - The medical device sector has shown strong performance, with the index rising over 3% and achieving a new annual high, driven by significant trading volume [2] - The Chinese medical device market is projected to reach 1.11 trillion yuan in 2024, growing by 12.3%, and is expected to exceed 1.3 trillion yuan by 2025 [2] - The AI medical device market is anticipated to reach 8.545 billion yuan in 2024, marking a year-on-year growth of 213.6%, with smart wearable medical devices seeing a 320% increase in sales [2] Group 3: Industry Trends and Future Outlook - The growth logic of the medical device industry is shifting from domestic substitution to internationalization and technological innovation, leading to a revaluation of the sector [3] - The optimization of procurement policies and improving bidding data are expected to contribute to a performance turning point for the medical device sector in the latter half of the year and into next year [3] - The rapid growth of new equipment procurement in the medical device sector is projected to increase by 41% year-on-year in the first half of 2025 [2]

Core Viewpoint - On August 11, Jiuding Investment (600053) announced a significant acquisition plan to acquire a 53.2897% stake in Nanjing Shenyuan Intelligent Technology Co., Ltd. for RMB 213 million, which will make it a subsidiary included in the consolidated financial statements [2][7]. Group 1: Acquisition Details - Jiuding Investment plans to acquire shares from multiple stakeholders, including 18.79% from Dai Zhendong for RMB 56.3745 million, 5.00% from Senlis for RMB 15 million, 3.00% from Zhao Haiying for RMB 9 million, 9.98% from Zhongke Haichuang for RMB 29.94 million, and 0.95% from Huiqing Investment for RMB 2.8443 million, totaling a 37.7196% stake for RMB 113 million [6][7]. - After the acquisition, Jiuding Investment intends to inject an additional RMB 100 million into Nanjing Shenyuan to acquire a further 25% stake, leading to a total investment of RMB 213 million for a 53.2897% stake [7]. Group 2: Company Background - Nanjing Shenyuan was established in 2012, founded by Professor Dai Zhendong from Nanjing University of Aeronautics and Astronautics, with a registered capital of RMB 7.01 million [5]. - The company specializes in six-dimensional force sensors and force measurement control, holding 21 invention patents (16 authorized) and 23 utility model patents, indicating a strong R&D capability [6]. Group 3: Market Potential - The previous financing round in December 2023 valued Nanjing Shenyuan at RMB 200 million, with limited market scope primarily in traditional industries [7]. - Recent trends show a growing application of six-dimensional force sensors in humanoid robots, significantly expanding market potential and improving future growth prospects [7].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 背景 持續關連交易 投資管理及諮詢協議 參照國浩於二零二二年十一月一日刊發的持續關連交易－投資管理及諮詢協議公告，內容有關 GAPL 分別與 AFAL 及 GMC 訂立二零二二年協議，由 GAPL 提供全權委託基金管理服務及投 資諮詢服務，年期由二零二二年十一月一日起至二零二五年十月三十一日止（包括首尾兩日）。 於二零二五年八月一日，AFAL 與 GAPL 訂立新投資管理協議，據此，GAPL 將根據新投資管 理協議的條款和條件，為 AFAL 提供與 IMA 投資組合相關的全權委託基金管理服務，年期由 二零二五年八月一日起至二零二八年六月三十日止（包括首尾兩日）。隨之，新投資管理協議 自二零二五年八月一日起取代並代替投資管理協議。 於二零二五年八月一日，GMC 與 GAPL 訂立協議書以重續投資諮詢及管理協議，年期由二零 二五年八月一日起至二零二八年六月三十日止（包括首尾兩日），投資諮詢及管理協議的所有 ...